請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64225
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 周綠蘋 | |
dc.contributor.author | Tsung-Chi Hu | en |
dc.contributor.author | 胡宗錡 | zh_TW |
dc.date.accessioned | 2021-06-16T17:35:41Z | - |
dc.date.available | 2017-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-15 | |
dc.identifier.citation | 1. International Agency for Research on Cancer. The Globocan Project [online], http://globocan.iarc.fr/ (2010).
2. Bartosch Birke. Hepatitis B and C viruses and hepatocellular carcinoma. Viruses. 2(8):1504-9 (2010). 3. Hashem B. El-Serag.Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142(6):1264-1273 (2012). 4. Department of Health, Excutive Yuan, R.O.C.(Taiwan). Cause of Death Statics [online], http://www.doh.gov.tw/(2011). 5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529-538 (2006). 6. American Cancer Society. Cancer Facts and FIGS 2005. American Cancer Society [online], http:// www.cancer.org/docroot/home/index.asp (2005). 7. American Cancer Society. Cancer Facts and FIGS 2005. American Cancer Society [online], http:// www.cancer.org/docroot/home/index.asp (2005). 8. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol. 46 Suppl 1:63-9. (2010). 9. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 22:788–93 (2007). 10. Chen CH, Huang MH, Yang JC et al. Prevalence and risk factors of non-alcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of non-alcoholic fatty liver disease in non-obese adults. J. Clin. Gastroenterol. 40: 745–52 (2006). 11. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics.J Hepatol. 52(2):252-7 (2009). 12. Köhler HH, Höhler T, Küsel U, Kirkpatrick CJ, Schirmacher P. Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report Pathol Res Pract. 195(7):509-13 (1999). 13. Evert M and Dombrowski F. Hepatocellular carcinoma in the non-cirrhotic liver Pathologe. 29(1): 47-52 (2008). 14. Ohira H, Abe K, Takahashi A, Zeniya M, Ichida T. Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. J Gastroenterol. 2012 Jun 13. [Epub ahead of print] 15. Salata H, Cortés JM, Enríquez de Salamanca R, Oliva H, Castro A, Kusak E, Carreño V, Hernandez Guío C. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J Hepatol. 1(5):477-87 (1985). 16. Siersema PD, ten Kate FJ, Mulder PG, Wilson JH. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver. 12(2):56-61 (1992). 17. Iwadate H, Ohira H, Suzuki T, Abe K, Yokokawa J, Takiguchi J, Rai T, Orikasa H, Irisawa A, Obara K, Kasukawa R, Sato Y. Hepatocellular carcinoma associated with Wilson's disease. Intern Med. 43(11): 1042-5 (2004). 18. Tagger A, Ribero ML, Larghi A, Donato F, Zuin M, Chiesa R, Benetti G, Ramella G, Borzio M, Podda M. Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease. Am J Gastroenterol. 94(2):484-8 (1999). 19. http://www.who.int/mediacenter/factsheets/fs204/en/ 20. Sung JL. Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 12(9-10):S370-6 (1997). 21. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 38 Suppl 2:S18-23 (1996). 22. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 11: 97–107 (2004). 23. Liaw YF and Chu CM. Hepatitis B virus infection. Lancet . 373: 582–592 (2009). 24. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 25(1):142-63 (2012). 25. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, Kim B, Roberts LR. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 9(1):64-70 (2011). 26. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 5:453–463 (2007). 27. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436–2441(2007). 28. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 362: 2095–2100 (2003). 29. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, Wu MH, Chen CJ. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan Am J Epidemiol. 157(8):674-82 (2003). 30. Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, Yuen MF, Lai CL, Kramvis A, Kew MC, Smuts HE, Netesov SV, Alter HJ, Mizokami M. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality Gastroenterology. 130 (3):703-14 (2006). 31. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 5(3):215-29 (2005). 32. Haydon GH, Jarvis LM, Simmonds P, Hayes PC. Association between chronic hepatitis C infection and hepatocellular carcinoma. Lancet. 345(8954):928-9 (1995). 33 Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 34 (4 Pt 1): 809–816 (2001). 34. Onyemelukwe CG, Nirodi C, West CE. Aflatoxin B1 in hepatocellular carcinoma. Trop Geogr Med. 32(3):237-40 (1980). 35. Rogers AE, Newberne PM. Nutrition and aflatoxin carcinogenesis. Nature. 229 (5279):62-3 (1971). 36. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 6(9):674-87 (2006). 37. McClain CJ, Hill DB, Song Z, Deaciuc I, Barve S. Monocyte activation in alcoholic liver disease. Alcohol. 27(1):53-61 (2002). 38. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci. 117(Pt 11):2417-26 (2004). 39. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene. 21(16):2593-604 (2002). 40. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 22(33):5093-107 (2003). 41. Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, Kasai H. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res. 54(12):3171-2 (1994) 42. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology. 127(5 Suppl 1):S62-71 (2004). 43. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 127(5 Suppl 1):S126-32 (2004). 44. Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I, Hassan S. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 8(1):53 (2011). 45. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology. 23(6):1334-40 (1996). 46. The METAVIR Cooperative Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 20(1 Pt 1):15-20 (1994). 47. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 56(7):968-73. Epub 2007 Jan 25 (2007). 48. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 41(1):48-54 (2005). 49. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 357(9262):1069-75 (2001). 50. Dalla Palma L, Pozzi-Mucelli RS, Bazzocchi M, Pozzi-Mucelli R, Ferrara P. Comparative evaluation of echography, computerized tomography and magnetic resonance imaging in the diagnosis of hepatocellular carcinoma in cirrhotic patients. Radiol Med. 81(1-2):8-15 (1991). 51. Cowan ML, Rahman TM, Krishna S. Proteomic approaches in the search for biomarkers of liver fibrosis. Trends Mol Med. 16(4):171-83 (2010). 52. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 128(2):343-50 (2005). 53. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 127(6):1704-13 (2004). 54. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med.1;139(1):46-50 (2003). 55. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, Kosaka K. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 99(2):508-18 (1990). 56. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, Seki T, Kudo M, Tanaka M. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol. 16(12):1378-83 (2001). 57. Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol. 91(7):1380-3 (1996). 58. Liebman HA, Furie BC, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gamma-carboxy prothrombin (abnormal prothrombin), a new serum marker for hepatocellular carcinoma. N Engl J Med 310:1427–1431 (1984). 59. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 3(2):79-87 (2007). 60. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 102(10):2196-205 (2007). 61. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 7(1):26-34 (2005). 62. Taylor CR, Garcia-Tsao G, Henson B, Case CQ, Taylor KJ. Doppler ultrasound in the evaluation of cirrhotic patients: the prevalence of intrahepatic arteriovenous shunting, and implications for diagnosis of hepatocellular carcinoma. Ultrasound Med Biol. 23(8):1155-63 (1997). 63. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 15(11):1301-14 (2009). 64. Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol. 11(39):6115-9 (2005). 65. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Palareti G, Gozzetti G. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg.1(4):249-55 (1995). 66. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis. 26(4):385-90 (2006). 67. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 53(3):1020-2 (2011). 68. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 69(3):89-95 (2001). 69. Urban D and Catane R. Serum tumor markers in oncology. Isr Med Assoc J. 11 (2) :103-4 (2009). 70. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 5(11):845-56 (2005). 71. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R, Williams KL, Humphery-Smith I. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis. 16(7):1090-4 (1995). 72. Desmetz C, Maudelonde T, Mangé A, Solassol J. Identifying autoantibody signatures in cancer: a promising challenge. Expert Rev Proteomics. 6(4):377-86 (2009). 73. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 96(5):353-6 (2004). 74. Poon TC, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor markers. Clin Chim Acta. 313(1-2):231-9 (2001). 75. May C, Brosseron F, Chartowski P, Meyer HE, Marcus K. Differential Proteome Analysis Using 2D-DIGE. Methods Mol Biol. 893:75-82 (2012). 76. Nafee AM, Pasha HF, El Aal SM, Mostafa NA. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma. Clin Biochem. 2012 May 2. [Epub ahead of print] 77. Sink TD, Lochmann RT, Fecteau KA. Validation, use, and disadvantages of enzyme-linked immunosorbent assay kits for detection of cortisol in channel catfish, largemouth bass, red pacu, and golden shiners. Fish Physiol Biochem. 34(1):95-101 (2007). 78. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012 Jun 25. [Epub ahead of print] 79. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol. 1(5):252-62 (2005). 80. Mueller LN, Brusniak MY, Mani DR, Aebersold R. An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J Proteome Res. 7(1):51-61 (2008). 81. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 76 (14):4193-201 (2004). 82. Simpson KL, Whetton AD, Dive C. Quantitative mass spectrometry-based techniques for clinical use: biomarker identification and quantification. J Chromatogr B Analyt Technol Biomed Life Sci. 877(13):1240-9 (2008). 83. Yergey AL, Esteban NV, Liberato DJ. Metabolic kinetics and quantitative analysis by isotope dilution thermospray LC/MS. Biomed Environ Mass Spectrom. 14 (11):623-5 (1987). 84. Tai SS, Welch MJ. Development and evaluation of a candidate reference method for the determination of total cortisol in human serum using isotope dilution liquid chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry. Anal Chem. 76(4):1008-14 (2004). 85. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J Mass Spectrom.44(12):1637-60 (2009). 86. Kiyonami R, Zeller M, Zabrouskov V. Quantifying peptides in complex mixtures with high sensitivity and precision using a targeted approach with a hybrid linear ion trap-orbitrap mass spectrometer. Thermo Scientific Application Note to be published. 87. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci. 877(13):1229-39 (2008). 88. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics. 4(2):175-86 (2007). 89. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A. 100(12):6940-5 (2003). 90. Pratt JM, Simpson DM, Doherty MK, Rivers J, Gaskell SJ, Beynon RJ. Multiplexed absolute quantification for proteomics using concatenated signature peptides encoded by QconCAT genes. Nat Protoc. 1(2):1029-43 (2006). 91. Dupuis A, Hennekinne JA, Garin J, Brun V. Protein Standard Absolute Quantification (PSAQ) for improved investigation of staphylococcal food poisoning outbreaks. Proteomics. 8(22):4633-6 (2008). 92. Brun V, Masselon C, Garin J, Dupuis A. Isotope dilution strategies for absolute quantitative proteomics. J Proteomics. 72(5):740-9 (2009). 93. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem. 389 (4):1017-31 (2007). 94. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, Anderson NL, Borchers CH. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics. 8(8):1860-77 (2009). 95. Cutillas PR, Vanhaesebroeck B. Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol Cell Proteomics. 6(9):1560-73 (2007). 96. Tabata T, Sato T, Kuromitsu J, Oda Y. Pseudo internal standard approach for label-free quantitative proteomics. Anal Chem. 79(22):8440-5 (2007). 97. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 17(10):994-9 (1999). 98. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 3(12):1154-69 (2004). 99. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 1(5):376-86 (2002). 100. Harsha HC, Molina H, Pandey A. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat Protoc. 3(3):505-16 (2008). 101. Oda Y, Huang K, Cross FR, Cowburn D, Chait BT. Accurate quantitation of protein expression and site-specific phosphorylation. Proc Natl Acad Sci U S A. 96(12):6591-6 (1999). 102. Yao X, Freas A, Ramirez J, Demirev PA, Fenselau C. Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus. Anal Chem. 73(13):2836-42 (2001). 103. Ludwig C, Claassen M, Schmidt A, Aebersold R. Estimation of absolute protein quantities of unlabeled samples by selected reaction monitoring mass spectrometry. Mol Cell Proteomics. 11(3):M111.013987 (2012). 104. America AH, Cordewener JH. Comparative LC-MS: a landscape of peaks and valleys. Proteomics. 8(4):731-49 (2008). 105. Petritis K, Kangas LJ, Ferguson PL, Anderson GA, Pasa-Tolić L, Lipton MS, Auberry KJ, Strittmatter EF, Shen Y, Zhao R, Smith RD. Use of artificial neural networks for the accurate prediction of peptide liquid chromatography elution times in proteome analyses. Anal Chem. 75(5):1039-48 (2003). 106. Conrads TP, Anderson GA, Veenstra TD, Pasa-Tolić L, Smith RD. Utility of accurate mass tags for proteome-wide protein identification. Anal Chem. 72(14):3349-54 (2000). 107. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, Mann M. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 4(9):1265-72 (2005). 108. Braisted JC, Kuntumalla S, Vogel C, Marcotte EM, Rodrigues AR, Wang R, Huang ST, Ferlanti ES, Saeed AI, Fleischmann RD, Peterson SN, Pieper R. The APEX Quantitative Proteomics Tool: generating protein quantitation estimates from LC-MS/MS proteomics results. BMC Bioinformatics. 9:529 (2008). 109. Lu P, Vogel C, Wang R, Yao X, Marcotte EM. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol. 25(1):117-24 (2006). 110. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics. 6(9):2865-73 (2006). 111. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 6(12):2212-29 (2007). 112. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat. 16(6):418-29 (2009). 113. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem. 53(10):1792-9 (2007). 114. Fortin T, Salvador A, Charrier JP, Lenz C, Bettsworth F, Lacoux X, Choquet-Kastylevsky G, Lemoine J. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal Chem. 81(22):9343-52 (2009). 115. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, Blaabjerg O, Blirup-Jensen S, Carlström A, Petersen PH, Johnson AM, Milford-Ward A, Ritchie RF, Svendsen PJ, Whicher J. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem. 34(6):517-20 (1996). 116. Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem.54(10):1608-16 (2008). 117. Fornell C,Larcker DF.Evaluating structural equation models with unobervables and measurement error.Journal of Marketing Research.18:39-50 (1981). 118. Gautier V, Mouton-Barbosa E, Bouyssie D, Delcourt N, Beau M, Girard JP, Cayrol C, Burlet-Schiltz O, Monsarrat B, Gonzalez de Peredo A. Label-free quantification and shotgun analysis of complex proteomes by 1D SDS-PAGE/nanoLC-MS: evaluation for the large-scale analysis of inflammatory human endothelial cells. Mol Cell Proteomics. 2012 Apr 19. [Epub ahead of print] 119. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 99(6):1160-74 (2004). 120. Thampanitchawong P, Piratvisuth T. Liver biopsy:complications and risk factors. World J Gastroenterol. 5(4):301-304 (1999). 121. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 24(8):971-83 (2006). 122. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. 1:1-48 (2007). 123. Consolo M, Amoroso A, Spandidos DA, Mazzarino MC. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease. Int J Mol Med. 24(2):143-52 (2009). 124. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci. 39(11):2426-32 (1994). 125. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 41(6):935-42 (2004). 126. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 8:241 (2008). 127. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res. 6(7):2631-9 (2007). 128. Qin S, Zhou Y, Lok AS, Tsodikov A, Yan X, Gray L, Yuan M, Moritz RL, Galas D, Omenn GS, Hood L. SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics.12(8):1244-52 (2012). 129. Musiał J. Beta2 glycoprotein-I--the main antigen in antiphospholipid syndrome Pol Arch Med Wewn. 117 Suppl:59-60 (2007). 130. Devreese KM. A functional coagulation test to identify anti-beta2-glycoprotein I dependent lupus anticoagulants. Thromb Res. 119(6):753-9 (2007). 131. Giannakopoulos B, Mirarabshahi P, Krilis SA. New insights into the biology and pathobiology of beta2-glycoprotein I. Curr Rheumatol Rep. 13(1):90-5 (2011). 132. Galazka M, Tang M, DeBari VA, Kohles JD, Lee JK, Keil LB, Petersheim M. Modification of beta 2 glycoprotein I by glutardialdehyde. Conformational changes and aggregation accompany exposure of the cryptic autoepitope. Appl Biochem Biotechnol. 76(1):1-13 (1999). 133. Willems GM, Janssen MP, Pelsers MM, Comfurius P, Galli M, Zwaal RF, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry. 35(43):13833-42 (1996). 134. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 1(11):845-67 (2002). 135. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 1(6):2856-60 (2006). 137. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 5(4):573-88 (2005). 138. Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, Barnes E, Klenerman P, Dwek RA, Zitzmann N. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One. 7(6):e39603 (2012). 139. White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, Skehel M, Liu C, Zekry A, Cutler P, Gattu M, Rockey DC, Berrey MM, McHutchison JG. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med. 5:33 (2007). 140. Zhang H, Liu Q, Zimmerman LJ, Ham AJ, Slebos RJ, Rahman J, Kikuchi T, Massion PP, Carbone DP, Billheimer D, Liebler DC. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol Cell Proteomics. 10(6):M110.006593 (2011). 141. Vaughn CP, Crockett DK, Lim MS, Elenitoba-Johnson KS. Analytical characteristics of cleavable isotope-coded affinity tag-LC-tandem mass spectrometry for quantitative proteomic studies. J Mol Diagn. 8(4):513-20 (2006). 142. Bachi A, Bonaldi T. Quantitative proteomics as a new piece of the systems biology puzzle. J Proteomics. 71(3):357-67 (2008). 143. UVic Proteomics Center. http://www.proteincentre.com/services/quantitative-proteomics (2009). 144. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem. 54(11):1796-804 (2008). 145. Bellei E, Bergamini S, Monari E, Fantoni LI, Cuoghi A, Ozben T, Tomasi A. High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids. 40(1):145-56 (2011). 146. Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics. 5(10):1957-67 (2006). 147. Calvo E, Camafeita E, Fernández-Gutiérrez B, López JA. Applying selected reaction monitoring to targeted proteomics. Expert Rev Proteomics. 8(2):165-73 (2011). 148. Collins BC, Miller CA, Sposny A, Hewitt P, Wells M, Gallagher WM, Pennington SR. Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach. Mol Cell Proteomics. 2012 Apr 23. [Epub ahead of print] | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64225 | - |
dc.description.abstract | 肝癌是目前世界上盛行率第三的惡性腫瘤。慢性C型肝炎患者的肝細胞因損傷而發炎,致使纖維化與結節化,最後形成肝硬化。而70%至80%的肝癌患者併有肝硬化,顯見若能儘早檢測出肝纖維化或硬化,對於肝癌病人的早期篩檢與治療評估,有相當大的幫助。生物標誌可反映出生物體的生理狀況。傳統上偵測蛋白質量的改變主要以抗體法為主,但因為發展適合的抗體有許多限制,而且抗體法無法同時針對數個蛋白同時進行偵測,使針對具潛力的生物標誌的驗證難以進行。質譜法定量蛋白體學可做為另外一種對生物標誌進行定量的方法。本論文的研究目的是以質譜儀開發免標法相對定量的平台,檢測並驗證C型肝炎病人血清中具潛力的生物標誌。透過文獻的搜尋與Western Blot的分析,我們發現Alpha-2-macroglobulin (A2M)、Alpha-1-B glycoprotein (A1BG)及Beta-2 glycoprotein (B2G1) 在C型肝炎帶原者 (chronic hepatitis C;CH-C) 、慢性C型肝炎併肝硬化 (CHC - LC) 及慢性C型肝炎病毒相關肝細胞癌併肝硬化 (CHC-HCC-LC) 三個群組中表現量高於正常人。接著用LTQ-Orbitrap Velos,以一維電泳膠體增強-液相層析質譜法 (1D gel-enhanced LC-MS;1D GeLCMS) 定量正常人與C型肝炎相關疾病患者血清中的潛力生物標誌。藉由全質譜掃描選出最適合的母離子做為目標胜肽。之後加入外源蛋白GroEL做為內標準物,以同樣方式選出參比胜肽,校準膠內水解法過程酵素活性作用不一以及後續胜肽粹取時產生的變異。最後以選擇離子偵測模式 (Selected Ion Monitoring;SIM)對C型肝炎相關疾病患者血清進行檢測,驗證A2M及A1BG的含量在C型肝炎相關疾病患者血清中表現量較高。 | zh_TW |
dc.description.abstract | HCC is the third most common cause of cancer-related deaths in the world. Patients with chronic liver inflammation and injury may lead to liver fibrosis, abnormal nodule formation and finally liver cirrhosis. Cirrhosis is seen in about 70-80% of HCC. The early detection of fibrosis and cirrhosis has important clinical implications in the diagnosis、assessment and treatment. Biomarker can be used as an indicator of a biological state. Traditionally, antibody-based methods are widely used to quantify the expression level of specific protein. However, there are many limitations to develop effective antibodies and hard to develop a multiplex assay. Mass spectrometry-based quantification methods has recently emerged as an alternative method for quantitation. In this study we developed a label-free quantitative platform for selectively examining multiple medium - abundance protein levels. Alpha-2-macroglobulin (A2M), alpha-1B-glycoprotein (A1BG) and Beta-2 glycoprotein (B2G1) were selected with literature search and then validated by western blot We found the concentration of all the three proteins were higher in HCV-related disease cohorts than in the normal. We then quantitated these three proteins by 1D Gel-enhanced LC-MS with LTQ-Orbitrap Velos. The best-flyer peptides of target proteins were confirmed in full scan mode as target peptides. Then we spiked an exogenous protein, GroEL, just prior to in-gel digestion as internal standard which can adjust for the differences from enzymatic activities and sample losses during experiment. Finally we validated that the concentration of A2M and A1BG were higher in HCV-related diseases cohorts than in normal in SIM scan mode. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T17:35:41Z (GMT). No. of bitstreams: 1 ntu-101-R99442016-1.pdf: 2591256 bytes, checksum: 99f3168181432ecaf4b62587baefb15d (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 摘要..................................................................i
Abstract..............................................................ii 縮寫................................................................iii 第一章 導論.........................................................1 1.1 肝癌.......................................................1 1.2 肝纖維化與肝硬化診斷方法...................................5 1.3 肝癌的診斷方法.............................................7 1.4 生物標誌..................................................10 1.5 蛋白質體學................................................11 1.6 研究動機..................................................20 1.7 實驗策略..................................................21 第二章 實驗材料....................................................23 2.1 生物檢體..................................................23 2.2 儀器及裝置................................................23 2.3 酵素與抗體................................................24 2.4 藥品與試劑組..............................................24 2.5 軟體......................................................25 第三章 實驗方法....................................................26 3.1 一維十二烷機磺酸鈉-聚丙烯醯胺膠體電泳分析 (1D SDS-PAGE) ..26 3.2 西方點墨法................................................27 3.3 質譜樣品之製備............................................29 3.4 液態層析串聯式質譜儀......................................30 3.5 軟體分析..................................................31 第四章 實驗結果....................................................34 4.1 具潛力的C型肝炎病毒相關疾病的生物標誌搜尋................34 4.2 以西方點墨法確認A2M、A1BG及B2G1為具潛力的生物標誌.......34 4.3 以A2M、A1BG及B2G1為模版開發免標法定量平台...............35 4.4 引入內標物(GroEL) ........................................37 4.5 以免標質譜法進行定量確認A2M、A1BG及B2G1為具潛力的生物標誌 ..........................................................40 第五章 討論........................................................43 5.1 肝癌化過程的生物標誌......................................43 5.2 實驗方法討論.............................................45 5.3 定量結果分析..............................................49 第六章 參考文獻....................................................53 第七章 圖表與說明..................................................71 附錄................................................................90 | |
dc.language.iso | zh-TW | |
dc.title | 以液相層析質譜儀對具潛力的C型肝炎相關疾病之生物標誌進行相對定量 | zh_TW |
dc.title | Relative Quantification of Potential Biomarkers of HCV-related Diseases by LC-MS/MS | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳頌方,徐志宏,陳健弘 | |
dc.subject.keyword | 肝癌,蛋白質體學,免標法相對定量,A2M,A1BG,B2G1, | zh_TW |
dc.subject.keyword | HCC,Proteomics,label-free quantification,A2M,A1BG,B2G1, | en |
dc.relation.page | 96 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 2.53 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。